Last edited by Vokinos
Friday, November 20, 2020 | History

4 edition of Whole-body effective half-lives for radiolabeled antibodies and related issues found in the catalog.

Whole-body effective half-lives for radiolabeled antibodies and related issues

Whole-body effective half-lives for radiolabeled antibodies and related issues

  • 356 Want to read
  • 10 Currently reading

Published by Division of Regulatory Applications, Office of Nuclear Regulatory Research, U.S. Nuclear Regulatory Commission, Supt. of Docs., U.S. G.P.O. [distributor] in Washington, DC .
Written in English

    Subjects:
  • Monoclonal antibodies,
  • Radioimmunotherapy,
  • Radioimmunoimaging,
  • Radiation -- Dosage

  • Edition Notes

    Other titlesWhole body effective half lives for radiolabeled antibodies and related issues.
    Statementprepared by D.G.L. Kaurin ... [et al.].
    ContributionsKaurin, D. G. L., U.S. Nuclear Regulatory Commission. Office of Nuclear Regulatory Research. Division of Regulatory Applications., Brookhaven National Laboratory.
    The Physical Object
    FormatMicroform
    Paginationxxv, 150 p.
    Number of Pages150
    ID Numbers
    Open LibraryOL17437724M
    OCLC/WorldCa36311267

    For example, antibodies of the invention may be engineered in the Fc-hinge domain to have increased in vivo or serum half-lives. Antibodies or fragments thereof with increased in vivo half-lives can be generated by attaching to said antibodies or antibody fragments polymer molecules such as high molecular weight polyethyleneglycol (PEG). Although the fast and slow half-lives (ti/2) for the two species are similar ( and minutes for the rat and and minutes for the human), inactivation is more severe in the rat, with 1 molecule of rat CYP enzyme lost for every 26 molecules of substrate metabolized, compared with a loss of 1 molecule of human enzyme for every. THC is highly lipid soluble, and plasma and urinary elimination half-lives are best estimated at days, where the rate-limiting step is the slow redistribution to plasma of THC sequestered in the tissues. Shorter half-lives are generally reported due to limited collection intervals and less sensitive analytical methods. This book contains introductory and state-of-the-art information on liposomes, monoclonal antibodies, use of polymers, implants, oral, transdermal, miscellaneous, intranasal, and ocular forms of drug delivery. Finally, a literature review on the regulatory and global aspects of drug delivery systems is presented.

    Such antibodies could be used to quantify hydrolyzable adducts in the supernatant after the adducts had been released from the protein and concentrated into a smaller volume. The use of antibodies that could recognize non-hydrolyzable adducts in situ would cut out even more steps in the analysis.


Share this book
You might also like
Engineering science data.

Engineering science data.

Aristotle: The poetics. Longinus: On the sublime. Demetrius: On style.

Aristotle: The poetics. Longinus: On the sublime. Demetrius: On style.

Orange Fairy Book

Orange Fairy Book

To sit on a horse.

To sit on a horse.

The divine life of Sri Sri Sitaramdas Omkarnath

The divine life of Sri Sri Sitaramdas Omkarnath

Cardinal Newman.

Cardinal Newman.

Consumer behavior

Consumer behavior

A treatise on opthalmy

A treatise on opthalmy

Molecular basis of cancer

Molecular basis of cancer

Jane Seymour

Jane Seymour

The hope-merchants

The hope-merchants

stained glass of Great Malvern Priory Church

stained glass of Great Malvern Priory Church

Chrysler Corporation 1985 service manual, rear wheel drive vans-wagons

Chrysler Corporation 1985 service manual, rear wheel drive vans-wagons

Francisco de Vitoria and his law of nation.

Francisco de Vitoria and his law of nation.

Gentle Rain with Music

Gentle Rain with Music

Whole-body effective half-lives for radiolabeled antibodies and related issues Download PDF EPUB FB2

Radiolabeled antibodies (RABs) are being developed and used in medical imaging and therapy in rapidly increasing numbers. Data on the whole body half effective half-lives were calculated from external dose rates obtained from attending physicians and radiation safety officers at participating.

Get this from a library. Whole-body effective half-lives for radiolabeled antibodies and related issues. [D G L Kaurin; U.S. Nuclear Regulatory Commission. Office of Nuclear Regulatory Research. Division of Regulatory Applications.; Brookhaven National Laboratory.;].

May 01,  · After efforts during more than 2 decades to implement the use of radiolabeled antibodies for cancer therapy, it is now appreciated (i) that many radionuclides and antibodies have potential applicability for this therapy, (ii) that antibody accretion remains the major limitation in delivering effective tumor radiation doses, and (iii) that Cited by: Molecular imaging and therapy of cancer with radiolabeled nanoparticles.

Author links open overlay panel Hao Hong a Yin Zhang b Jiangtao Sun a Weibo Cai a b c. and short circulation half-lives of most QD conjugates, while intellectual property-related issues may make pharmaceutical industry hesitant in taking part in this endeavor Cited by: Oct 01,  · This review summarizes the current state-of-the-art of radiolabeled nanoparticles for molecular imaging and internal radiotherapy applications targeting cancer.

With the capacity to provide enormous flexibility, radiolabeled nanoparticles have the potential to profoundly impact disease diagnosis and patient management in the near sunplena.com by: Nuclear medicine has long played a significant role in oncologic imaging, and the recent widespread clinical applications of positron emission tomography (PET) have further increased its importance.

As the prototype of molecular imaging, nuclear medicine interrogates metabolic and physiologic processes, rather than anatomy, and provides important in vivo information regarding tumor metabolism.

A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Immuno-positron emission tomography (immunoPET) with 89Zr-labeled antibodies has shown great potential in cancer imaging.

It can provide important information about the pharmacokinetics and tumor-targeting properties of monoclonal antibodies and may help in anticipating on toxicity. Furthermore, it allows accurate dose planning for individualized radioimmunotherapy and may aid in patient Cited by: The role of nuclear medicine in modern therapy of cancer.

Radiolabeled antibodies were developed for therapy. have longer half-lives (from hours to several days) as com. Oct 01,  · The inherent bone-seeking properties of radium ( Ra; see ref. 2) allows for the effective delivery to bone metastases.

The lack of suitable complexing agents for Ra limits its use for tumor-targeting moieties, such as antibodies, and hence broader utility in sunplena.com by: Phase I Study of Targeted Radioimmunotherapy for Leptomeningeal Cancers Using Intra-Ommaya I-3F8 A and B are the different half-lives associated with redistribution and Phase I studies of treatment of malignant gliomas and neoplastic meningitis with I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin Cited by: 64 Cu and 68 Ga are the most extensively researched and utilized radiometals in the construction of radiolabeled NPs for PET imaging because of handy radiolabeling methods and favorable decay half-lives [95,96].

64 Cu is generally produced by cyclotron accelerator and 68 Ga can be acquired from a commercial 68 Ge/ 68 Ga sunplena.com by: 8. Like many antibody-based tracers, PSMA-targeting radiolabeled antibodies penetrate tumor tissue poorly, have long blood retention, and have high background signal, thus necessitating delayed imaging with longer-lived isotopes like 89 Zr (half-life days) that exhibit troublesome dosimetry because of their long half-lives.

These issues relate to the increased risk of cancer due to radiation exposure, particularly as IBD patients already have a higher risk of colon cancer. However, PET is considered safe and the effective dose of whole-body 18 F-FDG was approximately 7 mSv, much less that the 16 mSv used for a routine abdominal–pelvic CT with contrast [63,64 Author: Nicole Dmochowska, Hannah R.

Wardill, Patrick A. Hughes. Peptide-Based 68Ga-PET Radiotracer for Imaging PD-L1 Expression in CancerCited by: 6. Sep 30,  · ICRP PUBLICATION Approved by the Commission in November Abstract–Radiopharmaceuticals are increasingly used for the treatment of various cancers with novel radionuclides, compounds, tracer molecules, and administration sunplena.com goal of radiation therapy, including therapy with radiopharmaceuticals, is to optimise the relationship between tumour control Author: Y.

Yonekura, S. Mattsson, G. Flux, W.E. Bolch, L.T. Dauer, D.R. Fisher, M. Lassmann, S. Palm, M. Hos. The clinical value of current and future nanomedicines can be improved by introducing patient selection strategies based on noninvasive sensitive whole-body imaging techniques such as positron emission tomography (PET).

Thus, a broad method to radiolabel and track preformed nanomedicines such as liposomal drugs with PET radionuclides will have a wide impact in sunplena.com by: Nov 30,  · Positron emission tomography (PET) is increasingly considered as an effective imaging method to support several stages of radiation therapy.

The combined usage of functional and morphological imaging in state‐of‐the‐art PET/CT scanners is rapidly emerging to support the treatment planning process in terms of improved tumor delineation, and to assess the tumor response in Cited by: You can write a book review and share your experiences.

Other readers will always be interested in your opinion of the books you've read. Whether you've loved the book or not, if you give your honest and detailed thoughts then people will find new books that are right for them. safety issues related to the toxicity and eco-toxicity of biocides.

It may also address questions relating to examination of the toxicity and eco-toxicity of chemical, biochemical and biological compounds whose use may have harmful consequences for human health. Zirconium is an effective radionuclide for antibody-based positron emission tomography (PET) imaging because its physical half-life ( h) matches the biological half-life of IgG antibodies.

Desferrioxamine (DFO) is currently the preferred chelator for 89Zr4+; however, accumulation of 89Zr in the bones of mice suggests that 89Zr4+ is released from DFO in sunplena.com by: Technetiumm (99m Tc) is a metastable nuclear isomer of technetium (itself an isotope of technetium), symbolized as 99m Tc, that is used in tens of millions of medical diagnostic procedures annually, making it the most commonly used medical radioisotope.

Technetiumm is used as a radioactive tracer and can be detected in the body by medical equipment (gamma cameras).Names: technetiumm, Tcm. The present invention relates to the design for the treatment, control or prevention of cancer, particularly metastatic cancer in the methods and compositions.

The method of the present invention comprises administering an effective amount of one or more EphA2 antibody binding and excited, thereby increasing EphA2 phosphorylation in cells and decreased levels of EphA2 has been sunplena.com by: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer.

The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been Cited by: Sep 01,  · Drugs with long half-lives are more likely to accumulate in human milk, and drugs with high oral bioavailability are more easily absorbed by the infant.

8 The adverse event profile of the drug is another property that affects the individual risk/benefit ratio. Use of a drug with a significant adverse effect in a lactating woman (such as an Cited by: Sep 30,  · Thus, the long half‐lives of commonly used SPECT isotopes makes imaging possible for slow biological processes (e.g., cell division, infection, and inflammation) and for validating the biodistribution of slowly localizing therapeutic radiopharmaceuticals.

Myocardial, brain, thyroid, and whole‐body bone SPECT have become routine in the sunplena.com by: Radiation Safety in Nuclear Medicine, Second Edition AND Table gives the half-lives of most commonly used medical radionuclides grouped by mode of decay.

Whole-body, effective. For metastatic disease, whole-body imaging sequences can add considerable time to the scan. Thus, such whole-body imaging is limited to one sequence (eg, DW or T2-weighted turbo spin echo) and/or postcontrast-enhanced MRI, which are the most time efficient methods of evaluating the bones in conjunction with sunplena.com: Edouard J.

Trabulsi, R. Bryan Rumble, Hossein Jadvar, Thomas Hope, Martin Pomper, Baris Turkbey, And. Full text of "Pesticides In The Modern World: Risks And Benefits" See other formats. Dec 16,  · If the radiolabeled glucose had been prepared in a growing plant, the naturally occurring glucose would have lowered the SA due to the non-radioactive glucose molecules.

The interest in these two is primarily related to the relatively long half-lives. PET imaging has been in use for several decades for human brain and whole body imaging Cited by: Feb 23,  · The commonest physical mechanism is of platelet circulatory half-life reduction caused by concurrent sepsis or coagulopathy e.g.

DIC. Immunological causes include induction of anti-HLA antibodies due to allosensitisation from previous transfusions or generation of /5. May 12,  · 1. Introduction. Molecular imaging techniques are now indispensable tools in modern diagnostics, because they are highly specific and can provide biological information at the molecular level in living systems.

1, 2 They have enabled visualization of some of the specific molecular events that play key roles in disease processes, and they have enabled earlier diagnosis, as well as monitoring of Cited by: Several different monoclonal antibodies and radiation isotopes have been utilized, with the goal of delivering increased doses of radiation to the sites of disease, for example, the marrow.

In one study, anti-CD33 antibodies conjugated to I were utilized in nine patients. Issuu is a digital publishing platform that makes it simple to publish magazines, catalogs, newspapers, books, and more online.

Easily share your publications and get them in front of Issuu’s. In addition, in some cases, compositions and methods of the invention provide sufficient increased affinity to the FcγRIIb receptor to allow for rapid clearance of the antibody-antigen complex while allowing appropriate serum half lives of the unbound antibodies.

The invention is. Branimir I. Sikic, M. is part of Stanford Profiles, official site for faculty, postdocs, students and staff information (Expertise, Bio, Research, Publications, and more). The site facilitates research and collaboration in academic endeavors. This banner text can have markup.

web; books; video; audio; software; images; Toggle navigation. The book starts with chapters that cover general drug delivery issues such as physicochemical and biological barriers, various pathways for drug delivery, for- mulation, pharmacokinetic and pharmacodynamic issues, metabolism, and cell cul- ture models used in studying drug delivery.

Then it moves on to cover specific drug delivery strategies. Each animal was iv administrated with 20 MBq of radiotracer (18F-Fluorine and 18F-FDG in two different days) under gas anaesthesia and then was allowed to wake up.

Uptake time was 60 minutes. The whole body scan (GE, eXplore Vista DR) was carried out under gas anaesthesia and images were reconstructed with OSEM 2D. His research interests include targeted delivery of oligonucleotides to the brain using non-viral vector-polymer conjugates, LC-MS/MS based method development and validation of small molecules and peptides, novel blood-brain barrier permeability markers, preclinical pharmacokinetics of small molecules and radiolabeled proteins/antibodies.

May 15,  · Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment said antibodies or fragments thereof immunospecifically bind to one or more RSV antigens and have increased in vivo half-lives, and wherein said effective amount is a dose of approximately 15 mg/kg or less of said antibodies or antibody fragments which results.Jan 19,  · The methods of the present invention also encompass the use of humanized antibodies or fragments thereof that have half-lives (e.g., serum half-lives) in a mammal, preferably a human, of greater than 15 days, preferably greater than 20 days, greater than 25 days, greater than 30 days, greater than 35 days, greater than 40 days, greater than Transcript.

1 The Toxicologist Supplement to Toxicological Sciences 54th Annual Meeting and ToxExpo TM MarchSan Diego, California The Official Journal of the Society of Toxicology ISSN VolumeIssue 1 March sunplena.com sunplena.com 2 55 th Society of Toxicology Annual Meeting and ToxExpo New Orleans, Louisiana March.